Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS) - Report - MDSpire
Advertisement
Management of ocular surface disease involving inflammation and persistent epithelial defects utilising various treatment modalities in the UK National Health Service (NHS)
Clinical Report: Approaches to Treating Inflammatory Ocular Surface Disease
Overview
This report evaluates the management of persistent corneal epithelial defects (PED) within the UK NHS, highlighting clinical outcomes, treatment burden, and economic costs associated with these cases.
Background
Persistent corneal epithelial defects (PED) can lead to complications, including vision loss. Management requires understanding its diverse aetiology and necessitates a stepwise treatment approach. There is limited data on treatment burden and costs associated with PED within the NHS.
Data Highlights
No numerical data available in the source material.
Key Findings
['PED is defined by failure of corneal re-epithelialisation beyond 10–14 days despite appropriate treatment.', 'Management of PED requires a multifactorial approach addressing both the underlying cause and promoting epithelial healing.', 'Common treatment modalities include intensive lubrication, bandage contact lenses, punctal plugs, and surgical options like amniotic membrane transplantation.', 'Chronic PEDs generate a high cumulative burden due to prolonged healing times and frequent monitoring.', 'There is a lack of unified coding for PED in national data systems, complicating evaluation of service impact.']
Clinical Implications
Healthcare professionals should be aware of the multifactorial nature of PED management.
Conclusion
The management of persistent corneal epithelial defects presents clinical and economic challenges within the NHS.
